Prelude Therapeutics (PRLD) Common Equity (2019 - 2026)
Prelude Therapeutics' Common Equity was $133.73 million in Q2 2026, up 76.3% from $75.84 million a year earlier and up 122.2% from the prior quarter.
Prelude Therapeutics (PRLD) Common Equity (2019 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at Prelude Therapeutics came in at $68.64 million, down 47.8% from FY2024.
- Common Equity shows a five-year compound annual growth rate of -20.2% (FY2020 to FY2025).
- In earlier years, Common Equity was $131.46 million in FY2024 (-44.6%), $237.09 million in FY2023 (+21.3%), $195.44 million in FY2022 (-31.6%) and $285.9 million in FY2021 (+34.7%).
- The Q2 2026 figure marks the highest quarterly Common Equity since Q3 2024.
- Compared with a year earlier, Common Equity was higher in 1 of the last eight quarters, with an average decline of 33.0%.
- The best year-over-year quarter for Common Equity over five years was Q2 2026 (growth of 76.3%); the worst was Q3 2025 (a decline of 62.6%).
- Per Business Quant data, PRLD's Common Equity in the three quarters before Q2 2026 was $60.18 million (Q1 2026), $68.64 million (Q4 2025) and $58.53 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Prelude Therapeutics | 312.03 Mn | -285.27 Mn | - | 133.73 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 133.73 Mn |
| Mar 31, 2026 | 60.18 Mn |
| Dec 31, 2025 | 68.64 Mn |
| Sep 30, 2025 | 58.53 Mn |
| Jun 30, 2025 | 75.84 Mn |
| Mar 31, 2025 | 103.18 Mn |
| Dec 31, 2024 | 131.46 Mn |
| Sep 30, 2024 | 156.43 Mn |
| Jun 30, 2024 | 182.28 Mn |
| Mar 31, 2024 | 210.73 Mn |
| Dec 31, 2023 | 237.09 Mn |
| Sep 30, 2023 | 238.26 Mn |
| Jun 30, 2023 | 262.06 Mn |
| Mar 31, 2023 | 175.30 Mn |
| Dec 31, 2022 | 195.44 Mn |
| Sep 30, 2022 | 217.41 Mn |
| Jun 30, 2022 | 240.84 Mn |
| Mar 31, 2022 | 261.81 Mn |
| Dec 31, 2021 | 285.90 Mn |
| Sep 30, 2021 | 311.24 Mn |
Prelude Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=PRLD&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "PRLD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=PRLD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();